PRAXIS PRECISION MEDICINES I

PRAXIS PRECISION MEDICINES I (PRAX)

$1.01

+0.13

(+15.15%)

Market is closed - opens 7 PM, 05 Jun 2023

Insights on PRAXIS PRECISION MEDICINES I

  • Vs SGEN

    In the last 1 year, Seagen Inc has given 44.0% return, outperforming this stock by 133.4%

Performance

  • $0.92
    $1.04
    $1.01
    downward going graph

    8.91%

    Downside

    Day's Volatility :11.54%

    Upside

    2.88%

    downward going graph
  • $0.79
    $8.75
    $1.01
    downward going graph

    21.78%

    Downside

    52 Weeks Volatility :90.97%

    Upside

    88.46%

    downward going graph

Returns

PeriodPRAXIS PRECISION MEDICINES ISector (Health Care)Index (Russel 2000)
3 Months
-69.96%
0.7%
-7.0%
6 Months
-59.95%
-7.9%
-6.5%
1 Year
-89.37%
-2.0%
-6.8%
3 Years
-96.84%
25.4%
24.7%

Highlights

Market Capitalization
53.0M
Book Value
$1.11
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-3.33
Wall Street Target Price
9.13
Profit Margin
0.0%
Operating Margin TTM
-26973.35%
Return On Assets TTM
-68.15%
Return On Equity TTM
-143.07%
Revenue TTM
683.0K
Revenue Per Share TTM
0.01
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-183.8M
Diluted Eps TTM
-3.33
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.67
EPS Estimate Next Year
-2.36
EPS Estimate Current Quarter
-0.79
EPS Estimate Next Quarter
-0.75

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for PRAXIS PRECISION MEDICINES I(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
9
Hold
2
4
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 803.96%

Current $1.01
Target $9.13

Technicals Summary

Sell

Neutral

Buy

PRAXIS PRECISION MEDICINES I is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
PRAXIS PRECISION MEDICINES I
PRAXIS PRECISION MEDICINES I
-14.84%
-59.95%
-89.37%
-96.84%
-96.84%
Moderna, Inc.
Moderna, Inc.
-2.19%
-29.52%
-8.32%
114.67%
590.97%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-8.43%
-4.6%
15.93%
18.38%
134.28%
Seagen, Inc.
Seagen, Inc.
-2.63%
59.03%
43.99%
21.05%
216.49%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-6.48%
0.7%
19.84%
13.84%
116.25%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
PRAXIS PRECISION MEDICINES I
PRAXIS PRECISION MEDICINES I
NA
NA
NA
-2.67
-1.43
-0.68
0.0
1.11
Moderna, Inc.
Moderna, Inc.
11.46
11.46
0.0
-1.9
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.91
19.91
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.18
26.18
0.41
14.61
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
PRAXIS PRECISION MEDICINES I
PRAXIS PRECISION MEDICINES I
Buy
$53.0M
-96.84%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$49.1B
590.97%
11.46
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$80.7B
134.28%
19.91
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.7B
216.49%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$83.3B
116.25%
26.18
35.4%

Institutional Holdings

  • Velan Capital Investment Management LP

    8.95%
  • Avidity Partners Management LP

    7.39%
  • Eventide Asset Management, LLC

    6.07%
  • BlackRock Inc

    5.13%
  • Verition Fund Managegment, LLC

    5.11%
  • Kingdon Capital Management LLC

    4.93%

Corporate Announcements

  • PRAXIS PRECISION MEDICINES I Earnings

    PRAXIS PRECISION MEDICINES I’s price-to-earnings ratio stands at None

    Read More

Company Information

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying insights from genetic epilepsies to broader neurological and psychiatric disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio, including multiple disclosed programs across CNS disorders including depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates.

Organization
PRAXIS PRECISION MEDICINES I
Employees
109
CEO
Mr. Marcio Souza M.B.A.
Industry
Health Technology

FAQs